Critical Reviews in Oncology / Hematology
Volume 76, Issue 1 , Pages 36-43, October 2010

The potential role of sunitinib in gastrointestinal cancers other than GIST

  • Cristina Grávalos

      Affiliations

    • Medical Oncology Department, 12 de Octubre Universitary Hospital, Avda. de Andalucía s/n Km 5.400, 28041 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 390 83 49; fax: +34 91 460 33 10.
    • ,
  • Enrique Grande

      Affiliations

    • Medical Oncology Department, Ramon y Cajal Universitary Hospital, Madrid, Spain
    • ,
  • Joan Manel Gasent

      Affiliations

    • Medical Oncology Department, Hospital Marina Alta de Denia, Alicante, Spain

Accepted 6 January 2010. published online 04 February 2010.

Abstract 

Gastrointestinal tumors are the most frequent and lethal malignancies worldwide. The deeper knowledge in molecular biology mechanisms involved in carcinogenesis has allowed the design of new targeted drugs mainly directed against the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Sunitinib is an oral multitargeted inhibitor of the VEGF, platelet-derived growth factor (PDGF), and c-KIT, among others, tyrosine kinase receptors. Therefore, sunitinib acts in a dual mode as antiangiogenic agent and as antitumoral drug. The aim of this review is to gather the preclinical rationale behind the clinical use of sunitinib in gastrointestinal malignancies other than gastrointestinal stromal tumors (GIST) and to summarize the clinical data from phase I to III trials currently available.

Keywords: Antiangiogenic therapy, Gastrointestinal cancer, Multitargeted therapy, Sunitinib, Tyrosine kinase inhibitor, VEGF

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(10)00009-0

doi:10.1016/j.critrevonc.2010.01.008

Critical Reviews in Oncology / Hematology
Volume 76, Issue 1 , Pages 36-43, October 2010

Article Tools

* Image Usage & Resolution